Mike is a member of Deloitte’s Global Lifescience and Healthcare leadership team. He acts as a strategic advisor and leads transformational programmes for major pharmaceutical companies, healthcare systems, medical charities and governments. His areas of expertise include:
- Corporate strategy and business model innovation – working with leading pharma on portfolio restructuring, business growth, and organisational redesign.
- Next generation strategy – leads the 21st century Pharma Company programme which looks at options to re-design of pharma companies to operate in the changing environments
- Integrated healthcare – developed new models of care for cancer and diabetics, integrating drugs, protocols and devices. Redesigned cancer and cardiovascular comorbidity management programmes
Mike was a founder member of GMEC, Europe’s largest medical cluster, which linked Oxford and Cambridge Universities with UCL, Imperial and Kings College. He is also an Advisory Board member of the BHF Data Science Centre and presents at major conferences
Mike works on building life science clusters and has extensive experience working with government, pharma companies and healthcare systems in the US, Canada, Europe and Australia.
Competing Interest Disclosure statement for Mike Standing in 2021.